Ceruvia raises $8M to fully fund headache drug trial
What's the deal? Ceruvia LifesciencesDealroom has a profile for this one. Try Dealroom →, a Greenwich, Connecticut-based biopharmaceutical company, has raised $8 million to advance clinical development of BOL-148, a proprietary non-hallucinogenic LSD analog for cluster headache. The founder-backed investment fully funds an integrated Phase 1/2 clinical study.
What's the endgame? The single study bridges from healthy-volunteer dose escalation into proof-of-concept evaluation in patients. Part 1 is a standard Phase 1 single ascending dose test in healthy adults; Part 2 is a randomised, placebo-controlled Phase 2 study in cluster headache patients to demonstrate safety and efficacy.
Ceruvia plans to submit its Clinical Trial Application in Germany in September 2026, with first enrollment expected in the fourth quarter. Phase 1 top-line data is expected in the second quarter of 2027, after which the study progresses to the Phase 2 portion. Results will support a Phase 3 pivotal trial in the US and EU.
Why now? "Over the past two years we've refined both the science and the development strategy behind this program," said founder and chief executive officer Carey Turnbull. He added the capital puts Ceruvia "in a position to evaluate both the safety and therapeutic potential of BOL-148 within a single clinical study."
What's the need? Cluster headache, often called the "suicide headache," is one of the most severe neurological pain disorders. Treatment options remain limited, and there are no FDA-approved preventive therapies for chronic cluster headache. BOL-148 builds on a Harvard Medical SchoolDealroom has a profile for this one. Try Dealroom → trial in which chronic patients achieved complete, durable response, plus Ceruvia's own Phase 1 safety data.
What could go wrong? The drug is unproven at scale, and the integrated design compresses two trial stages into one — meaning early Phase 1 results must hold up before the patient study proceeds. A Phase 3 pivotal trial remains years away.
The signal: At $8 million, the round sits at the 53.5th percentile by amount among comparable deals — a modest but sufficient sum for a targeted, fully funded study. Founded in 2017, Ceruvia reflects growing investor interest in derivatives of psychedelic compounds engineered to remove the hallucinogenic effect while retaining therapeutic potential.
Read more: PR Newswire
Image credit: Ceruvia Lifesciences
